Jiazhen Dong

Jiazhen Dong

Auto-generated profile, based on publicly available information

Jiazhen Dong

State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
LBLei Bai
Lei Bai
JDJiazhen Dong
Jiazhen Dong
ZLZhenqiu Liu
Zhenqiu Liu
YRYouliang Rao
Youliang Rao
PFPinghui Feng
Pinghui Feng
Ke LanKe Lan
Ke Lan
Methionine oxidation by viperin is critical for the expression and function of helicases.

6 December 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
FDFabin Dang
Fabin Dang
LBLei Bai
Lei Bai
JDJiazhen Dong
Jiazhen Dong
XHXiaoping Hu
Xiaoping Hu
JWJingchao Wang
Jingchao Wang
WWWenyi Wei
Wenyi Wei
Targeting angiotensin-converting enzyme 2 (ACE2) represents a promising and effective approach to combat not only the COVID-19 pandemic but also potential future pandemics arising from coronaviruses that depend on ACE2 for infection. Here, we report ubiquitin specific peptidase 2 (USP2) as a host-directed antiviral target; we further describe the development of MS102, an orally available USP2 inhibitor with viable antiviral activity against ACE2-dependent coronaviruses. Mechanistically, USP2 serves as a physiological deubiquitinase of ACE2, and targeted inhibition with specific small-molecule inhibitor ML364 leads to a marked and reversible reduction in ACE2 protein abundance, thereby blocking various ACE2-dependent coronaviruses tested. Using human ACE2 transgenic mouse models, we further demonstrate that ML364 efficiently controls disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as evidenced by reduced viral loads and ameliorated lung inflammation. Furthermore, we improved the in vivo performance of ML364 in terms of both pharmacokinetics and antiviral activity. The resulting lead compound, MS102, holds promise as an oral therapeutic option for treating infections with coronaviruses that are reliant on ACE2.